Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer

Oncotarget

Volumn 7, Issue 1, 2016, Pages 610-621

  Xie, Caifeng ^a   Jin, Jiangbo ^a   Bao, Xujie ^a   Zhan, Wei Hua ^a   Han, Tian Yu ^a   Gan, Mingxi ^a   Zhang, Chengfu ^a   Wang, Jianbin ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Erlotinib; Glutaminase inhibitor 968; Non small cell lung cancer

Indexed keywords

5 [3 BROMO 4 (DIMETHYLAMINO)PHENYL] 2,2 DIMETHYL 2,3,5,6 TETRAHYDROBENZO[A]PHENANTHRIDIN 4(1H) ONE; COMPOUND 968; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLUTAMINASE; GLUTAMINASE C INHIBITOR; GLUTAMINE; MITOCHONDRIAL ENZYME; UNCLASSIFIED DRUG; BENZOPHENANTHRIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

AMINO ACID METABOLISM; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME INHIBITION; GAC GENE; GENE; GENE KNOCKDOWN; GLUTAMINE METABOLISM; GLYCOLYSIS; HCC827ER CELL LINE; HUMAN; HUMAN CELL; NCI-H1975 CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; LUNG TUMOR; METABOLISM; MITOCHONDRION; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BENZOPHENANTHRIDINES; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; FLOW CYTOMETRY; GLUTAMINASE; HUMANS; LUNG NEOPLASMS; MITOCHONDRIA; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; TIME FACTORS;

EID: 85013081652     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.6311     Document Type: Article

References (49)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 cancer incidence and mortality worldwide: IARC cancerbase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Int J Cancer. 2015; 136:E359-86
2. Bray F. Transitions in human development and the global cancer burden. In: Wild CP, Stewart B, eds. World cancer report 2014. Lyon: International Agency for Research on Cancer, 2014
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-86
4. Rebecca Siegel, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal DVM. Cancer Statistics, 2014. CA Cancer J Clin. 2014; 64:9-29
5. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours, pathology and genetics: tumours of the lung, pleura, thymus and heart. Lyon: IARC, 2004
6. Sakashita S, Sakashita M, Sound Tsao M. Genes and pathology of non-small cell lung carcinoma. Semin Oncol. 2014; 41:28-39
7. Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR, Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther. 2013; 12:2200-12
8. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002; 62:5749-54
9. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther. 2005; 27:1513-34
10. Lee CC, Shiao HY, Wang WC, Hsieh HP. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs. 2014; 23:1333-48
11. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009; 28 Suppl 1:S24-31
12. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28:357-60
13. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104:20932-7
14. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105:2070-5
15. Yang SH. Molecular basis of drug resistance: epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors. Tuberc Respir Dis (Seoul). 2013; 75:188-98
16. Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respir Investig. 2014; 52:82-91
17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-33
18. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011; 10:671-84
19. Yi Zhang, Jin-Ming Yang. Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention. Cancer Biol Ther. 2013; 14:81-89
20. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-14
21. Serizawa M, Kusuhara M, Zangiacomi V, Urakami K, Watanabe M, Takahashi T, Yamaguchi K, Yamamoto N, Koh Y. Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. Anticancer Res. 2014; 34:2779-87
22. Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H, Tsuchihara K. Epidermal Growth Factor Receptor (EGFR) Signaling Regulates Global metabolic Pathways in EGFR-mutated Lung Adenocarcinoma. J Biol Chem. 2014; 289:20813-20823
23. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013; 123:3678-84
24. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget. 2010; 1:734-40
25. Mohamed A, Deng X, Khuri FR, Owonikoko TK. Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer. 2014; 15:7-15
26. Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics. 1999; 1:51-62
27. van den Heuvel AP, Jing J, Wooster RF, Bachman KE. Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012; 13:1185-94
28. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18:207-19
29. Lukey MJ, Wilson KF, Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem. 2013; 5:1685-700
30. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007; 7:169-81
31. Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res. 2007; 13:1540-51
32. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5:341-354
33. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 2010; 10:760-774
34. Okabe T, Okamoto I, Tamura K, Terashima M, Yoshida T, Satoh T, Takada M, Fukuoka M, Nakagawa K. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007; 67:2046-2053
35. Katt WP, Cerione RA. GLS regulation in cancer cells: a druggable chain of events. Drug Discov Today. 2014; 19:450-7
36. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2:e73
37. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006; 12:6494-501
38. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316:1039-43
39. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3:75ra26
40. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010; 16:5489-98
41. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, Jiang F, Song JJ, Wei W, Hurov JB. Full-length human GLS in complex with an allosteric inhibitor. Biochemistry. 2011; 50:10764-70
42. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, Hansen JC, Curthoys NP. Novel mechanism of inhibition of rat kidney-type GLS by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 2007; 406:407-14
43. Catane R, Von HoffDD, Glaubiger DL, Muggia FM. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat Rep. 1979; 63:1033-8
44. Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced nonsmall cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010; 5:1855-8
45. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced nonsmall cell lung cancer: meta-analysis of phase III trials. Lung Cancer. 2011; 74:469-73
46. Wang JB, Wu WJ, Cerione RA. Cdc42 and Ras cooperate to mediate cellular transformation by intersectin-L. J Biol Chem. 2005; 280:22883-91
47. Kenny J, Bao Y, Hamm B, Taylor L, Toth A, Wagers B, Curthoys NP. Bacterial expression, purification and characterization of rat kidney-type mitochondrial GLS. Protein Expr. Purif. 2003; 31: 140-148
48. Aalim M. Weljie, Jack Newton, Pascal Mercier, Erin Carlson, Carolyn M. Slupsky. Targeted Profiling: Quantitative Analysis of 1H NMR metabolomics Data. Anal. Chem. 2006; 78:4430-4442
49. Djomangan Adama Ouattara, Jean-Matthieu Prot, Andrei Bunescu, Marc-Emmanuel Dumas, Bénédicte Elena-Herrmann, Eric Leclerc, Céline Brochot. Metabolomicson-a-chip and metabolic flux analysis for label-free modeling of the internal Metabolism of HepG2/C3A cells. Mol. BioSyst. 2012; 8:1908-1920